More information <\/b>about MODAG’s research results<\/p>\n<\/div><\/div><\/div>Questions & Answers<\/span><\/a><\/div><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | <\/span>SAA PD DETECT<\/a> | <\/span>PET tracer<\/a><\/p>\n<\/div>PublicationsOur scientific publications<\/span><\/h3><\/div><\/div><\/div><\/a><\/span><\/div>Emrusolmin (anle138<\/a>b)<\/span><\/a><\/h3><\/div>Emrusolmin (anle138b) is an innovative oligomer modulator that has the potential to influence the course of neurodegenerative diseases such as multiple system atrophy.<\/span> Detailed information on the mode of action and the promising study results can be found here.<\/span><\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/a><\/span><\/div> SAA (Seed Amplification Assay): PD DETECT<\/a><\/a><\/h3><\/div>SAA technology, also known as RT-QuIC, enables the highly sensitive and specific detection of misfolded proteins such as alpha-synuclein and prions in biological samples.<\/span> This method offers promising approaches for the early diagnosis and monitoring of neurodegenerative diseases. Read more here. <\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/a><\/span><\/div> <\/a>PET tracer<\/a><\/a><\/h3><\/div>Our research on PET tracers aims to visualize pathological protein deposits such as alpha-synuclein<\/span> in order to better diagnose neurodegenerative diseases and monitor their progression. You can find out more about this in our publications. <\/span><\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>Emrusolmin (anle138b)<\/h2><\/div>NATURE COMMUNICATIONS<\/h3><\/div>The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>THE LANCET – eBioMedicine<\/b><\/h3><\/div>Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomized, double-blind, placebo-controlled phase 1a trial.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ACS Chemical Neuroscience<\/h3><\/div>Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>EMBO Molecular Medicine<\/h3><\/div>The diphenylpyrazole compound anle138b blocks Ab channels and rescues disease phenotypes in a mouse model for amyloid pathology.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Movement Disorders<\/h3><\/div>Anle138b Modulates \u03b1-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Alzheimer’s Research & Therapy<\/h3><\/div>Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Our aim is to<\/span> develop novel therapeutics based on the molecular principles.<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>SAA \/ RT-QuIC<\/h2><\/div>Acta Neuropathologica<\/h3><\/div>A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica Communications<\/h3><\/div>Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Journal of Neuropathology & Experimental Neurology<\/h3><\/div>Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>FEBS Open Bio<\/h3><\/div>Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Faster and more precise diagnoses<\/span><\/strong>with PD DETECT<\/span><\/h3><\/div>SAA:<\/span><\/strong>The future of protein diagnostics<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>PET tracer development<\/h2><\/div>European Journal of Nuclear Medicine and Molecular Imaging<\/h3><\/div>[MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ChemMedChem<\/h3><\/div>\u00b9\u00b9C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to \u03b1-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.<\/p>\n<\/div>
Emrusolmin<\/a><\/span> | <\/span>SAA PD DETECT<\/a> | <\/span>PET tracer<\/a><\/p>\n<\/div>PublicationsOur scientific publications<\/span><\/h3><\/div><\/div><\/div><\/a><\/span><\/div>Emrusolmin (anle138<\/a>b)<\/span><\/a><\/h3><\/div>Emrusolmin (anle138b) is an innovative oligomer modulator that has the potential to influence the course of neurodegenerative diseases such as multiple system atrophy.<\/span> Detailed information on the mode of action and the promising study results can be found here.<\/span><\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/a><\/span><\/div> SAA (Seed Amplification Assay): PD DETECT<\/a><\/a><\/h3><\/div>SAA technology, also known as RT-QuIC, enables the highly sensitive and specific detection of misfolded proteins such as alpha-synuclein and prions in biological samples.<\/span> This method offers promising approaches for the early diagnosis and monitoring of neurodegenerative diseases. Read more here. <\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/a><\/span><\/div> <\/a>PET tracer<\/a><\/a><\/h3><\/div>Our research on PET tracers aims to visualize pathological protein deposits such as alpha-synuclein<\/span> in order to better diagnose neurodegenerative diseases and monitor their progression. You can find out more about this in our publications. <\/span><\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>Emrusolmin (anle138b)<\/h2><\/div>NATURE COMMUNICATIONS<\/h3><\/div>The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>THE LANCET – eBioMedicine<\/b><\/h3><\/div>Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomized, double-blind, placebo-controlled phase 1a trial.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ACS Chemical Neuroscience<\/h3><\/div>Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>EMBO Molecular Medicine<\/h3><\/div>The diphenylpyrazole compound anle138b blocks Ab channels and rescues disease phenotypes in a mouse model for amyloid pathology.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Movement Disorders<\/h3><\/div>Anle138b Modulates \u03b1-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Alzheimer’s Research & Therapy<\/h3><\/div>Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Our aim is to<\/span> develop novel therapeutics based on the molecular principles.<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>SAA \/ RT-QuIC<\/h2><\/div>Acta Neuropathologica<\/h3><\/div>A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica Communications<\/h3><\/div>Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Journal of Neuropathology & Experimental Neurology<\/h3><\/div>Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>FEBS Open Bio<\/h3><\/div>Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Faster and more precise diagnoses<\/span><\/strong>with PD DETECT<\/span><\/h3><\/div>SAA:<\/span><\/strong>The future of protein diagnostics<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>PET tracer development<\/h2><\/div>European Journal of Nuclear Medicine and Molecular Imaging<\/h3><\/div>[MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ChemMedChem<\/h3><\/div>\u00b9\u00b9C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to \u03b1-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.<\/p>\n<\/div>
Emrusolmin (anle138b) is an innovative oligomer modulator that has the potential to influence the course of neurodegenerative diseases such as multiple system atrophy.<\/span> Detailed information on the mode of action and the promising study results can be found here.<\/span><\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/a><\/span><\/div> SAA (Seed Amplification Assay): PD DETECT<\/a><\/a><\/h3><\/div>SAA technology, also known as RT-QuIC, enables the highly sensitive and specific detection of misfolded proteins such as alpha-synuclein and prions in biological samples.<\/span> This method offers promising approaches for the early diagnosis and monitoring of neurodegenerative diseases. Read more here. <\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/a><\/span><\/div> <\/a>PET tracer<\/a><\/a><\/h3><\/div>Our research on PET tracers aims to visualize pathological protein deposits such as alpha-synuclein<\/span> in order to better diagnose neurodegenerative diseases and monitor their progression. You can find out more about this in our publications. <\/span><\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>Emrusolmin (anle138b)<\/h2><\/div>NATURE COMMUNICATIONS<\/h3><\/div>The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>THE LANCET – eBioMedicine<\/b><\/h3><\/div>Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomized, double-blind, placebo-controlled phase 1a trial.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ACS Chemical Neuroscience<\/h3><\/div>Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>EMBO Molecular Medicine<\/h3><\/div>The diphenylpyrazole compound anle138b blocks Ab channels and rescues disease phenotypes in a mouse model for amyloid pathology.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Movement Disorders<\/h3><\/div>Anle138b Modulates \u03b1-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Alzheimer’s Research & Therapy<\/h3><\/div>Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Our aim is to<\/span> develop novel therapeutics based on the molecular principles.<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>SAA \/ RT-QuIC<\/h2><\/div>Acta Neuropathologica<\/h3><\/div>A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica Communications<\/h3><\/div>Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Journal of Neuropathology & Experimental Neurology<\/h3><\/div>Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>FEBS Open Bio<\/h3><\/div>Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Faster and more precise diagnoses<\/span><\/strong>with PD DETECT<\/span><\/h3><\/div>SAA:<\/span><\/strong>The future of protein diagnostics<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>PET tracer development<\/h2><\/div>European Journal of Nuclear Medicine and Molecular Imaging<\/h3><\/div>[MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ChemMedChem<\/h3><\/div>\u00b9\u00b9C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to \u03b1-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.<\/p>\n<\/div>
SAA technology, also known as RT-QuIC, enables the highly sensitive and specific detection of misfolded proteins such as alpha-synuclein and prions in biological samples.<\/span> This method offers promising approaches for the early diagnosis and monitoring of neurodegenerative diseases. Read more here. <\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/a><\/span><\/div> <\/a>PET tracer<\/a><\/a><\/h3><\/div>Our research on PET tracers aims to visualize pathological protein deposits such as alpha-synuclein<\/span> in order to better diagnose neurodegenerative diseases and monitor their progression. You can find out more about this in our publications. <\/span><\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>Emrusolmin (anle138b)<\/h2><\/div>NATURE COMMUNICATIONS<\/h3><\/div>The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>THE LANCET – eBioMedicine<\/b><\/h3><\/div>Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomized, double-blind, placebo-controlled phase 1a trial.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ACS Chemical Neuroscience<\/h3><\/div>Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>EMBO Molecular Medicine<\/h3><\/div>The diphenylpyrazole compound anle138b blocks Ab channels and rescues disease phenotypes in a mouse model for amyloid pathology.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Movement Disorders<\/h3><\/div>Anle138b Modulates \u03b1-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Alzheimer’s Research & Therapy<\/h3><\/div>Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Our aim is to<\/span> develop novel therapeutics based on the molecular principles.<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>SAA \/ RT-QuIC<\/h2><\/div>Acta Neuropathologica<\/h3><\/div>A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica Communications<\/h3><\/div>Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Journal of Neuropathology & Experimental Neurology<\/h3><\/div>Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>FEBS Open Bio<\/h3><\/div>Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Faster and more precise diagnoses<\/span><\/strong>with PD DETECT<\/span><\/h3><\/div>SAA:<\/span><\/strong>The future of protein diagnostics<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>PET tracer development<\/h2><\/div>European Journal of Nuclear Medicine and Molecular Imaging<\/h3><\/div>[MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ChemMedChem<\/h3><\/div>\u00b9\u00b9C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to \u03b1-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.<\/p>\n<\/div>
Our research on PET tracers aims to visualize pathological protein deposits such as alpha-synuclein<\/span> in order to better diagnose neurodegenerative diseases and monitor their progression. You can find out more about this in our publications. <\/span><\/p>\n<\/div>To the publications<\/span><\/a><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>Emrusolmin (anle138b)<\/h2><\/div>NATURE COMMUNICATIONS<\/h3><\/div>The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>THE LANCET – eBioMedicine<\/b><\/h3><\/div>Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomized, double-blind, placebo-controlled phase 1a trial.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ACS Chemical Neuroscience<\/h3><\/div>Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>EMBO Molecular Medicine<\/h3><\/div>The diphenylpyrazole compound anle138b blocks Ab channels and rescues disease phenotypes in a mouse model for amyloid pathology.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Movement Disorders<\/h3><\/div>Anle138b Modulates \u03b1-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Alzheimer’s Research & Therapy<\/h3><\/div>Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Our aim is to<\/span> develop novel therapeutics based on the molecular principles.<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>SAA \/ RT-QuIC<\/h2><\/div>Acta Neuropathologica<\/h3><\/div>A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica Communications<\/h3><\/div>Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Journal of Neuropathology & Experimental Neurology<\/h3><\/div>Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>FEBS Open Bio<\/h3><\/div>Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Faster and more precise diagnoses<\/span><\/strong>with PD DETECT<\/span><\/h3><\/div>SAA:<\/span><\/strong>The future of protein diagnostics<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>PET tracer development<\/h2><\/div>European Journal of Nuclear Medicine and Molecular Imaging<\/h3><\/div>[MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ChemMedChem<\/h3><\/div>\u00b9\u00b9C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to \u03b1-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.<\/p>\n<\/div>
Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>Emrusolmin (anle138b)<\/h2><\/div>NATURE COMMUNICATIONS<\/h3><\/div>The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>THE LANCET – eBioMedicine<\/b><\/h3><\/div>Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomized, double-blind, placebo-controlled phase 1a trial.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ACS Chemical Neuroscience<\/h3><\/div>Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>EMBO Molecular Medicine<\/h3><\/div>The diphenylpyrazole compound anle138b blocks Ab channels and rescues disease phenotypes in a mouse model for amyloid pathology.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Movement Disorders<\/h3><\/div>Anle138b Modulates \u03b1-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica<\/h3><\/div>Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Alzheimer’s Research & Therapy<\/h3><\/div>Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Our aim is to<\/span> develop novel therapeutics based on the molecular principles.<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>SAA \/ RT-QuIC<\/h2><\/div>Acta Neuropathologica<\/h3><\/div>A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica Communications<\/h3><\/div>Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Journal of Neuropathology & Experimental Neurology<\/h3><\/div>Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>FEBS Open Bio<\/h3><\/div>Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Faster and more precise diagnoses<\/span><\/strong>with PD DETECT<\/span><\/h3><\/div>SAA:<\/span><\/strong>The future of protein diagnostics<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>PET tracer development<\/h2><\/div>European Journal of Nuclear Medicine and Molecular Imaging<\/h3><\/div>[MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ChemMedChem<\/h3><\/div>\u00b9\u00b9C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to \u03b1-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.<\/p>\n<\/div>
The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils.<\/p>\n<\/div>
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomized, double-blind, placebo-controlled phase 1a trial.<\/p>\n<\/div>
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease.<\/p>\n<\/div>
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.<\/p>\n<\/div>
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.<\/p>\n<\/div>
Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.<\/p>\n<\/div>
The diphenylpyrazole compound anle138b blocks Ab channels and rescues disease phenotypes in a mouse model for amyloid pathology.<\/p>\n<\/div>
Anle138b Modulates \u03b1-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy.<\/p>\n<\/div>
Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model.<\/p>\n<\/div>
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau.<\/p>\n<\/div>
Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>SAA \/ RT-QuIC<\/h2><\/div>Acta Neuropathologica<\/h3><\/div>A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Acta Neuropathologica Communications<\/h3><\/div>Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Journal of Neuropathology & Experimental Neurology<\/h3><\/div>Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>FEBS Open Bio<\/h3><\/div>Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>Faster and more precise diagnoses<\/span><\/strong>with PD DETECT<\/span><\/h3><\/div>SAA:<\/span><\/strong>The future of protein diagnostics<\/span><\/h3><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>PET tracer development<\/h2><\/div>European Journal of Nuclear Medicine and Molecular Imaging<\/h3><\/div>[MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ChemMedChem<\/h3><\/div>\u00b9\u00b9C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to \u03b1-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.<\/p>\n<\/div>
A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.<\/p>\n<\/div>
Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.<\/p>\n<\/div>
Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.<\/p>\n<\/div>
Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.<\/p>\n<\/div>
Emrusolmin<\/a><\/span> | SAA PD DETECT<\/a> | PET tracer<\/a><\/p>\n<\/div>PET tracer development<\/h2><\/div>European Journal of Nuclear Medicine and Molecular Imaging<\/h3><\/div>[MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates.<\/p>\n<\/div>Read publication<\/span><\/a><\/div>ChemMedChem<\/h3><\/div>\u00b9\u00b9C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to \u03b1-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.<\/p>\n<\/div>
[MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates.<\/p>\n<\/div>
\u00b9\u00b9C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to \u03b1-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.<\/p>\n<\/div>